P53-MDM2 PATHWAY: EVIDENCES FOR A NEW TARGETED THERAPEUTIC APPROACH IN B-ACUTE LYMPHOBLASTIC LEUKEMIA
The tumor suppressor p53 is a canonical regulator of different biological functions, like apoptosis, cell cycle arrest, DNA repair and genomic stability. This gene is frequently altered in human tumors generally by point mutations or deletions. Conversely, in acute lymphoblastic leukemia (ALL) genom...
Main Authors: | Stefania Trino, Luciana De Luca, Ilaria Laurenzana, Antonella Caivano, Luigi Del Vecchio, Giovanni Martinelli, Pellegrino Musto |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00491/full |
Similar Items
-
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
by: Khurana A, et al.
Published: (2019-04-01) -
Clinical overview of MDM2/X targeted therapies
by: Andrew eBurgess, et al.
Published: (2016-01-01) -
Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma
by: Joon Hee Kang, et al.
Published: (2020-06-01) -
TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
by: Chiao-En Wu, et al.
Published: (2019-03-01) -
MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
by: Samy A. Azer
Published: (2018-03-01)